All In Biotech

NDA 018916 · Hospira

Heparin Sodium 25,000 Units In Sodium Chloride 0.9% In Plastic Container

Heparin Sodium · Injection

Last checked: Nov 21, 2026Latest source record: Nov 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Jan 31, 1984

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,126

334 Phase 3, 112 recruiting

FAERS reports

14,058

11,053 serious, 2,653 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 12, 2026.

HEPARIN SODIUM IN SODIUM CHLORIDE INJECTION is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism; • Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation; • Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); • Prevention of clotting in arterial and cardiac surgery; • Prophylaxis and treatment of peripheral arterial embolism; • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. HEPARIN SODIUM IN SODIUM CHLORIDE INJECTION is indicated for: ( 1 ) • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation • Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Anticoagulant use in blood transfusions, extracorporeal circulation and dialysis procedures

Mechanism: Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo . Heparin acts at multiple sites in the normal coagulation system. Small amounts of heparin in combination with antithrombin III (heparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 23, 1989 Supplement 8 · Efficacy
  • Jan 31, 1984 Original approval · Type 5 - New Formulation or New Manufacturer
11 products under this application
  • HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · HEPARIN SODIUM 5,000 UNITS/100ML · INJECTABLE, INJECTION · Discontinued
  • HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER · HEPARIN SODIUM 5,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription
  • HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% · HEPARIN SODIUM 10,000 UNITS/100ML · INJECTABLE, INJECTION · Discontinued
  • HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · HEPARIN SODIUM 200 UNITS/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% · HEPARIN SODIUM 5,000 UNITS/100ML · INJECTABLE, INJECTION · Discontinued
  • HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% · HEPARIN SODIUM 1,000 UNITS/100ML · INJECTABLE, INJECTION · Discontinued
  • HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER · HEPARIN SODIUM 10,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription
  • HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER · HEPARIN SODIUM 5,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription
  • HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45% · HEPARIN SODIUM 100 UNITS/ML · INJECTABLE, INJECTION · Discontinued
  • HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · HEPARIN SODIUM 200 UNITS/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9% · HEPARIN SODIUM 10,000 UNITS/100ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Heparin" as an intervention, any sponsor and status, largest first.

All 1,126 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • heparin-induced thrombocytopenia1,293
  • drug ineffective1,043
  • off label use787
  • nausea754
  • drug hypersensitivity643
  • vomiting620
  • hypotension571
  • dyspnoea558
  • pulmonary embolism519
  • sepsis503
  • pyrexia499
  • anaemia488

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004464
2005225
2006189
2007127
20081,029
2009247
2010472
2011403
2012356
2013329
2014276
2015367
2016402
2017527
2018642
2019796
2020705
2021975
20221,141
20231,251
20241,027
2025998
20261,110

Recalls

3 FDA enforcement reports for this application.

  • Dec 29, 2022 · Class II · Completed

    Lack of assurance of sterility: Bags have the potential to leak.

  • Sep 11, 2014 · Class I · Terminated

    Presence of Particulate Matter: A particulate, confirmed as human hair, was found sealed between the tube and film at the round seal of the unused administrative port of the container.

  • Jan 9, 2014 · Class II · Terminated

    Lack of Assurance of Sterility; potential leakage from administrative port.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20).

  • Current · updated Nov 9, 2026

    Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,575 on PubMed

Sponsor: Pfizer · Also marketed as Heparin Sodium 25,000 Units In Sodium Chloride 0.45% In Plastic Container, Heparin Sodium 10,000 Units In Sodium Chloride 0.45%, Heparin Sodium 2,000 Units In Sodium Chloride 0.9% In Plastic Container, Heparin Sodium 12,500 Units In Sodium Chloride 0.9%, Heparin Sodium 5,000 Units In Sodium Chloride 0.9%

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.